Compare Novartis AG (NVS) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Sibanye Stillwater Ltd — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Sibanye Stillwater Ltd trades at $8.59 (market cap $5.66B). The key difference: Novartis AG is far larger — about 51.3× Sibanye Stillwater Ltd's market cap, and Sibanye Stillwater Ltd pays the higher dividend (3.89%). Which is the better fit depends on your goals.
| NVS | SBSW | |
|---|---|---|
Market Cap | $290.25B | $5.66B |
Sector | Health | Basic Materials |
52-Week High | $168.62 | $21.12 |
52-Week Low | $113.50 | $7.27 |
Enterprise Value | $330.27B | $7.28B |
Dividend Yield | 3.17% | 3.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.
The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.
SBSW trades at $8.59, up 7.38% today, but remains in a bearish technical trend with negative profitability metrics. The company reported a net loss of $7.30B in 2024 despite $112.13B revenue, though 2025 projections show improved EBITDA of $21.4B. Analyst consensus is mixed with 42.9% buy ratings and a $14.25 price target, representing 66% upside potential from current levels.
The stock presents a high-risk turnaround opportunity with deep value characteristics (P/E 4.76, P/S 0.72) but faces significant execution risks amid negative ROE and ROA. Key catalysts include management's debt reduction targets and operational improvements, while commodity price volatility remains a major headwind for the mining company.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
